Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry

J Biol Chem. 2011 Sep 16;286(37):31984-92. doi: 10.1074/jbc.M111.269605. Epub 2011 Jul 15.

Abstract

The HCV envelope glycoproteins E1 and E2 contain eight and 18 highly conserved cysteine residues, respectively. Here, we examined the oxidation state of E1E2 heterodimers incorporated into retroviral pseudotyped particles (HCVpp) and investigated the significance of free sulfhydryl groups in cell culture-derived HCV (HCVcc) and HCVpp entry. Alkylation of free sulfhydryl groups on HCVcc/pp with a membrane-impermeable sulfhydryl-alkylating reagent 4-(N-maleimido)benzyl-α-trimethylammonium iodide (M135) prior to virus attachment to cells abolished infectivity in a dose-dependent manner. Labeling of HCVpp envelope proteins with EZ-Link maleimide-PEG2-biotin (maleimide-biotin) detected free thiol groups in both E1 and E2. Unlike retroviruses that employ disulfide reduction to facilitate virus entry, the infectivity of alkylated HCVcc could not be rescued by addition of exogenous reducing agents. Furthermore, the infectivity of HCVcc bound to target cells was not affected by addition of M135 indicative of a change in glycoprotein oxidation state from reduced to oxidized following virus attachment to cells. By contrast, HCVpp entry was reduced by 61% when treated with M135 immediately following attachment to cells, suggesting that the two model systems might demonstrate variations in oxidation kinetics. Glycoprotein oxidation was not altered following binding of HCVpp incorporated E1E2 to soluble heparin or recombinant CD81. These results suggest that HCV entry is dependent on the presence of free thiol groups in E1 and E2 prior to cellular attachment and reveals a new essential component of the HCV entry process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkylating Agents / pharmacology
  • Alkylation / drug effects
  • Cysteine / metabolism*
  • HEK293 Cells
  • Hepacivirus / metabolism*
  • Humans
  • Oxidation-Reduction / drug effects
  • Protein Multimerization / physiology*
  • Quaternary Ammonium Compounds / pharmacology
  • Recombinant Proteins / metabolism
  • Tetraspanin 28 / metabolism
  • Viral Envelope Proteins / metabolism*
  • Virus Internalization*

Substances

  • Alkylating Agents
  • CD81 protein, human
  • E1 protein, Hepatitis C virus
  • Quaternary Ammonium Compounds
  • Recombinant Proteins
  • Tetraspanin 28
  • Viral Envelope Proteins
  • glycoprotein E2, Hepatitis C virus
  • 4-(N-maleimido)benzyltrimethylammonium
  • Cysteine